{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:25:17Z","timestamp":1790483117610,"version":"4.1.0"},"reference-count":25,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Xenobiotica"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1080\/00498254.2020.1839982","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T14:22:22Z","timestamp":1603203742000},"page":"222-238","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Preclinical\n            <i>in\u00a0vitro<\/i>\n            and\n            <i>in\u00a0vivo<\/i>\n            pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy"],"prefix":"10.1080","volume":"51","author":[{"given":"Mark P.","family":"Grillo","sequence":"first","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Markova","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA"},{"name":"Jazz Pharmaceuticals Inc, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Evanchik","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA"},{"name":"Drug Metabolism and Pharmacokinetics, Assembly Biosciences Inc R&amp;D Main Facility, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Trellu","sequence":"additional","affiliation":[{"name":"DMPK Research Platform France, Sanofi-Aventis Recherche et D\u00e9veloppement, Chilly Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Moliner","sequence":"additional","affiliation":[{"name":"Sanofi, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Brun","sequence":"additional","affiliation":[{"name":"DMPK Research Platform France, Sanofi-Aventis Recherche et D\u00e9veloppement, Chilly Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Perreard-Dumaine","sequence":"additional","affiliation":[{"name":"DMPK Research Platform France, Sanofi-Aventis Recherche et D\u00e9veloppement, Alfortville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7590-7729","authenticated-orcid":false,"given":"Pascale","family":"Vicat","sequence":"additional","affiliation":[{"name":"DMPK Research Platform France, Sanofi-Aventis Recherche et D\u00e9veloppement, Alfortville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3736-1673","authenticated-orcid":false,"given":"James P.","family":"Driscoll","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim J.","family":"Carlson","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/019262339502300203"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01062336"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/074823379701300401"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx015574b"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018943613122"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.117606"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0218-3"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2013.105"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.590"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-742-6_3"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(96)00339-6"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2005.03.008"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920007780866799"},{"key":"e_1_3_3_15_1","first-page":"1350","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in\u00a0vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach R.S.","year":"1999","unstructured":"Obach, R.S., 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in\u00a0vitro half-life approach and nonspecific binding to microsomes. Drug metabolism and disposition, 27, 1350\u20131359.","journal-title":"Drug metabolism and disposition"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.020750"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.02.051"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22552"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00969"},{"key":"e_1_3_3_20_1","unstructured":"United States Food and Drug Administration\u2019s Guidance for Industry: In\u00a0Vitro Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.065581"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1933"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.6.647"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.6.612"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01881.x"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.05.011"}],"container-title":["Xenobiotica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00498254.2020.1839982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T07:59:28Z","timestamp":1729065568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00498254.2020.1839982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1080\/00498254.2020.1839982"],"URL":"https:\/\/doi.org\/10.1080\/00498254.2020.1839982","relation":{},"ISSN":["0049-8254","1366-5928"],"issn-type":[{"value":"0049-8254","type":"print"},{"value":"1366-5928","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ixen20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ixen20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}